8-KMaterial AgreementsFinancial EventsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Mar 8, 2022)

Filed March 8, 2022For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report detailing material definitive agreements related to its corporate headquarters and laboratory space. The company, through its subsidiary Old Saw Mill Holdings LLC, has extended a $720.0 million lease financing agreement for its New York-based facilities. This extension spans five years, moving the maturity date from March 2022 to March 2027. The amended agreements involve a restated participation agreement and a restated lease, which govern the financing and the company's use of the property. These extensions provide continued operational stability and maintain the existing financing structure for these critical assets. The terms include variable interest rates based on SOFR plus a spread and margin, and Regeneron continues to operate under a triple-net lease structure for the facility. The company retains options for further extension or a potential purchase of the facility at maturity.

Key Highlights

  • 1Regeneron extended its $720.0 million lease financing for its corporate headquarters and laboratory facilities by five years, now maturing in March 2027.
  • 2The extension was executed through Second Amended and Restated Participation and Lease Agreements.
  • 3The lease remains a triple-net lease, with Regeneron responsible for maintenance, insurance, and taxes, partially offset by subleasing income.
  • 4The financing costs are tied to a variable rate based on SOFR, plus a spread adjustment and an applicable margin.
  • 5Regeneron and certain subsidiaries have provided a restated guaranty for the lessee's obligations.
  • 6The company has options to further extend the lease for an additional five years or to purchase the facility at maturity.
  • 7The amended agreements include financial covenants such as maximum total leverage ratio and minimum interest expense coverage ratio, similar to existing credit facilities.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce the extension of a significant lease financing agreement for Regeneron's corporate headquarters and laboratory facilities located in New York. This extension ensures continued access to and use of these critical operational assets for an additional five years.

The lease financing of $720.0 million has been extended by five years to March 2027. The interest rate payable on the financing is variable, linked to SOFR plus a spread, which means the cost of financing could fluctuate. Regeneron also continues to operate under a triple-net lease, meaning it covers operational costs like maintenance, insurance, and taxes for the facility.

Yes, Regeneron has several options. It can elect to extend the lease and financing for an additional five-year period, subject to participant consent. Alternatively, it has the option to purchase the facility outright for the outstanding principal amount plus accrued interest and other costs, or to sell the facility to a third party on behalf of the lessor, all under specific terms and conditions.

The restated agreements include financial and operating covenants that are substantially similar to those in Regeneron's existing Credit Agreement. These include maintaining a maximum total leverage ratio and a minimum interest expense coverage ratio, along with customary limitations on subsidiary indebtedness, liens, fundamental changes, affiliate transactions, and restricted payments (like dividends).